Abstract | BACKGROUND: Experimental findings suggest that the obese Zucker rat (OZR) is a model of type 2 diabetes-related nephropathy with several metabolic abnormalities. However, the exact mechanisms by which these factors cause early glomerulosclerosis and proteinuria remain unclear. Furthermore, structural abnormalities and regulation of podocytes have recently emerged as prominent underlying factors in proteinuria. The aim of this study was to evaluate the potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in an experimental model of type 2 diabetes mellitus. METHODS: RESULTS: Glomerular lesions were correlated with cholesterol (r = 0.676), proteinuria (r = 0.804), triglycerides (r = 0.593), insulin (r = 0.345), creatinine (r = 0.266), and glucose (r = 0.245). In addition, podocytes from OZR showed positive staining for desmin. Use of the ACE inhibitor quinapril normalized proteinuria, cholesterol levels, glomerular lesions, and podocyte morphology. In contrast, atorvastatin ameliorated but did not normalize renal damage, with a partial reduction in desmin staining and podocyte morphology. Treatment with both drugs resulted in only a slight reduction in IL-8 and IP-10 in the tubulointerstitium. CONCLUSIONS: In the OZR, cholesterol was an important determinant of renal injury. Most notably, glomerulosclerosis in the OZR Is characterized by early podocyte damage and tubulointerstitial injury. In addition, our findings showed that quinapril primarily normalized podocyte morphology, whereas atorvastatin ameliorated renal lesions through the diminution of lipids and by its lipid-independent pleiotropic effect.
|
Authors | Sandra Blanco, Manuel Vaquero, Carmen Gómez-Guerrero, Dolores López, Jesús Egido, Ramón Romero |
Journal | American journal of hypertension
(Am J Hypertens)
Vol. 18
Issue 4 Pt 1
Pg. 557-65
(Apr 2005)
ISSN: 0895-7061 [Print] United States |
PMID | 15831368
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrroles
- Tetrahydroisoquinolines
- Atorvastatin
- Quinapril
|
Topics |
- Angiotensin-Converting Enzyme Inhibitors
(pharmacology)
- Animals
- Atorvastatin
- Diabetes Mellitus, Type 2
(pathology)
- Diabetic Nephropathies
(pathology)
- Disease Models, Animal
- Glomerulosclerosis, Focal Segmental
(pathology)
- Heptanoic Acids
(pharmacology)
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(pharmacology)
- Hypertension
(complications)
- Immunoenzyme Techniques
- Kidney
(drug effects, pathology)
- Kidney Glomerulus
(metabolism, pathology)
- Linear Models
- Microscopy, Electron
- Obesity
(complications)
- Pyrroles
(pharmacology)
- Quinapril
- Rats
- Rats, Zucker
- Staining and Labeling
- Tetrahydroisoquinolines
(pharmacology)
|